Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 3,183	$ 3,663	$ 8,696	$ 14,294
Research and development
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	789	447	2,190	5,003
General and administrative
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 2,394	$ 3,216	$ 6,506	$ 9,291